Dendron-polymer hybrid mediated anticancer drug delivery for suppression of mammary cancer
Journal of Materials Science & Technology, ISSN: 1005-0302, Vol: 63, Page: 115-123
2021
- 9Citations
- 13Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations9
- Citation Indexes9
- CrossRef1
- Captures13
- Readers13
- 13
Article Description
Dendron-polymer-based nanoscale and stimuli-responsive drug delivery systems have shown great promise in tumor-targeting accumulation without significant toxicity. Here we report a dendronized polymer-doxorubicin (DOX) hybrid (DPDH) with an improved in vivo drug delivery efficiency for cancer therapy compared with a linear polymer-DOX conjugate (LPDC). The in vitro drug release profile of DOX indicates that DPDH displays pH-responsive drug release due to cleavage of hydrazone bonds since a greater amount of DOX is released at pH 5.2 at a faster rate than at pH 7.4. DPDH efficiently enters 4T1 cells and releases DOX to induce cytotoxicity and apoptosis. Owing to the dendronzied structure, DPDH has a significantly longer blood circulation time than LPDC. DPDH substantially enhances the therapeutic efficacy to suppress tumor growth in a 4T1 mammary cancer model than LPDC as well as free drug, evidenced from tumor growth inhibition, TUNEL assessment and histological analysis. Biosafety of DPDH is also confirmed from hemolysis, body weight shifts during treatment and pathological analysis. This study demonstrates the use of dendronized polymer-DOX hybrids for specific drug molecules is a promising approach for drug delivery.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1005030220304448; http://dx.doi.org/10.1016/j.jmst.2020.02.089; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85087217610&origin=inward; https://linkinghub.elsevier.com/retrieve/pii/S1005030220304448; https://api.elsevier.com/content/article/PII:S1005030220304448?httpAccept=text/xml; https://api.elsevier.com/content/article/PII:S1005030220304448?httpAccept=text/plain; https://dul.usage.elsevier.com/doi/; http://sciencechina.cn/gw.jsp?action=cited_outline.jsp&type=1&id=6915435&internal_id=6915435&from=elsevier; https://dx.doi.org/10.1016/j.jmst.2020.02.089
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know